Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Bicycle Therapeutics is a biotechnology business based in the US. Bicycle Therapeutics shares (BCYC) are listed on the NASDAQ and all prices are listed in US Dollars. Bicycle Therapeutics employs 119 staff and has a trailing 12-month revenue of around $15 million.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $27.96 |
|---|---|
| 52-week range | $12.08 - $51.93 |
| 50-day moving average | $29.08 |
| 200-day moving average | $24.21 |
| Wall St. target price | $53.64 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.91 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $27.96 from 2023-01-25
| 1 week (2023-01-20) | 1.82% |
|---|---|
| 1 month (2022-12-27) | -1.27% |
| 3 months (2022-10-27) | 16.50% |
| 6 months (2022-07-27) | 14.83% |
| 1 year (2022-01-27) | -39.64% |
|---|---|
| 2 years (2021-01-27) | 8.92% |
| 3 years (2020-01-27) | 151.89% |
| 5 years (2018-01-23) | N/A |
| Revenue TTM | $15 million |
|---|---|
| Gross profit TTM | $-33,183,000 |
| Return on assets TTM | -18.34% |
| Return on equity TTM | -43.79% |
| Profit margin | 0% |
| Book value | $9.75 |
| Market capitalisation | $816.5 million |
TTM: trailing 12 months
We're not expecting Bicycle Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Bicycle Therapeutics's shares have ranged in value from as little as $12.08 up to $51.932. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bicycle Therapeutics's is 0.7746. This would suggest that Bicycle Therapeutics's shares are less volatile than average (for this exchange).
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
